Support and Resistance Levels
Past performance
About Amwill Health Care Ltd Amwill Health Care Limited, incorporated in 2017 and headquartered in Bangalore, Karnataka, specializes in the development of dermatological and cosmeceutical products. Originally operating as a private entity, it transitioned to a public limited company in January 2024. The company primarily focuses on problem-solving dermatological, cosmeceutical, and aesthetic solutions, leveraging contract manufacturers, distributors, and third-party developers for manufacturing, packaging, and distribution operations. This outsourcing model allows Amwill to concentrate on its core strength—product formulation and development.
Amwill's product offerings are divided into generic dermatological solutions and tailored formulations for specific dermatological issues. Notable launches include *XL-HYDRA*, a facial moisturizer introduced in 2020, and *Fin-XL Pro Gel*, a hair-care therapy solution in gel form launched in 2021. Many of its marketed products were initially developed under the proprietorship of its promoter, Anand Gandhi. To streamline its supply chain, Amwill has established a structured storage and distribution network through its promoter group entity, M/s. Amderma Healthcare LLP. A formal Carrying and Forwarding Agreement was signed with Amderma in May 2024 to enhance distribution efficiency.
The company is preparing for an Initial Public Offering (IPO) to raise capital through the issuance of 62,00,000 equity shares, comprising a fresh issue of 50,00,000 shares and an Offer for Sale of 12,00,000 shares. The IPO signals Amwill’s growth ambitions, which could potentially scale its research, development, and distribution footprint. With a growing portfolio and evolving market presence, Amwill Health Care Limited is positioned as a niche player in the expanding derma-cosmetic and cosmeceutical sectors.